Literature DB >> 25980622

Cellular uptake and in vivo distribution of polyhistidine peptides.

Takashi Iwasaki1, Yoshihisa Tokuda2, Ayaka Kotake2, Hiroyuki Okada3, Shuji Takeda3, Tsuyoshi Kawano2, Yuji Nakayama4.   

Abstract

Cell-penetrating peptides (CPPs) are arginine/lysine-rich sequences, and they are effectively internalized into cells. In this process, positive charge is crucial. In the present study, we found polyhistidine peptides (PHPs), as the novel CPP, which are efficiently internalized into cells in a positive charge-independent manner. Interestingly, cellular uptake of the PHPs increased as the chain length increased, reaching a maximum uptake at H16 (HHHHHHHHHHHHHHHH-NH2). This H16 peptide showed up to 14.6-fold higher cell-penetrating capacity against HT1080 human fibrosarcoma cells relative to a major CPP, the octa-arginine (RRRRRRRR-NH2) peptide. Cellular uptake of the H16 peptide is mainly due to macropinocytosis and most of the H16 peptide localizes in the lysosome and Golgi apparatus. However, a cytoplasmic pro-apoptotic domain (KLAKLAKKLAKLAK-NH2) conjugated to the H16 peptide showed cytotoxic effects. This indicates that a proportion of the H16 peptide escapes from the macropinosome to the cytoplasm. In a protein transduction study, green fluorescence protein fused to the H16 peptide (GFP-H16) was purified by Ni-NTA chromatography, detected using an anti-His-tag antibody and internalized into cells. This serial process reveals that H16 functions as a His-tag and protein transduction domain. Furthermore, in vivo distribution analysis showed that the H16 peptide accumulates immediately in tumor tissue and is retained up to 132h following injection into the tumor (HT1080 human fibrosarcoma)-bearing mice. This is the first observation of a His-polymer being internalize into cells efficiently. The findings suggest that PHPs are novel CPPs. In particular, the H16 peptide represents a promising drug delivery carrier candidate in medical and biotechnological fields.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell-penetrating peptide (CPP); Endocytosis; Histidine; Human fibrosarcoma; Macropinocytosis

Mesh:

Substances:

Year:  2015        PMID: 25980622     DOI: 10.1016/j.jconrel.2015.05.268

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Enhanced Cellular Uptake Of Phenamil Through Inclusion Complex With Histidine Functionalized β-Cyclodextrin As Penetrative Osteoinductive Agent.

Authors:  Vahid Jahed; Ebrahim Vasheghani-Farahani; Fatemeh Bagheri; Ali Zarrabi; Trine Fink; Kim Lambertsen Larsen
Journal:  Int J Nanomedicine       Date:  2019-10-11

2.  Polyhistidine facilitates direct membrane translocation of cell-penetrating peptides into cells.

Authors:  Han-Jung Lee; Yue-Wern Huang; Shiow-Her Chiou; Robert S Aronstam
Journal:  Sci Rep       Date:  2019-06-28       Impact factor: 4.379

3.  Development of Organelle Replacement Therapy Using a Stearyl-Polyhistidine Peptide against Lysosomal Storage Disease Cells.

Authors:  Taiki Hayashi; Riku Okamoto; Tsuyoshi Kawano; Takashi Iwasaki
Journal:  Molecules       Date:  2019-08-18       Impact factor: 4.411

4.  Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers.

Authors:  Noriko Hirai; Takaaki Sasaki; Shunsuke Okumura; Yoshinori Minami; Shinichi Chiba; Yoshinobu Ohsaki
Journal:  Front Oncol       Date:  2020-04-02       Impact factor: 6.244

Review 5.  Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer.

Authors:  Savvas Papageorgiou; Sarah L Pashley; Laura O'Regan; Sam Khan; Richard Bayliss; Andrew M Fry
Journal:  Cancers (Basel)       Date:  2022-07-15       Impact factor: 6.575

6.  Synthesis and Characterization of Radiogallium-Labeled Cationic Amphiphilic Peptides as Tumor Imaging Agents.

Authors:  Takeshi Fuchigami; Takeshi Chiga; Sakura Yoshida; Makoto Oba; Yu Fukushima; Hiromi Inoue; Akari Matsuura; Akira Toriba; Morio Nakayama
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.